

Michael Dougan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2043658/publications.pdf>

Version: 2024-02-01

89
papers

6,748
citations

136885

32
h-index

79644

73
g-index

90
all docs

90
docs citations

90
times ranked

12777
citing authors

#	ARTICLE	IF	CITATIONS
1	Tissue eosinophils express the IL-33 receptor ST2 and type 2 cytokines in patients with eosinophilic esophagitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 656-660.	2.7	8
2	A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load. <i>Clinical Infectious Diseases</i> , 2022, 75, e440-e449.	2.9	46
3	Engineering T cell memory for antitumor immunity. <i>Trends in Pharmacological Sciences</i> , 2022, 43, 1-3.	4.0	2
4	The Landscape of COVID-19 Research in the United States: a Cross-sectional Study of Randomized Trials Registered on ClinicalTrials.gov. <i>Journal of General Internal Medicine</i> , 2022, 37, 154-161.	1.3	4
5	Elevated circulating memory T cells precede immunotherapy toxicities in melanoma. <i>Trends in Cancer</i> , 2022, . .	3.8	7
6	Antigen identification and high-throughput interaction mapping by reprogramming viral entry. <i>Nature Methods</i> , 2022, 19, 449-460.	9.0	32
7	Case Report: Fulminant Celiac Disease With Combination Immune Checkpoint Therapy. <i>Frontiers in Immunology</i> , 2022, 13, 871452.	2.2	8
8	Case 14-2022: A 57-Year-Old Man with Chylous Ascites. <i>New England Journal of Medicine</i> , 2022, 386, 1834-1844.	13.9	0
9	AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor Colitis and Hepatitis: Expert Review. <i>Gastroenterology</i> , 2021, 160, 1384-1393.	0.6	121
10	Liver biopsy findings in patients on immune checkpoint inhibitors. <i>Modern Pathology</i> , 2021, 34, 426-437.	2.9	48
11	Type 2 immunity is maintained during cancer-associated adipose tissue wasting. <i>Immunotherapy Advances</i> , 2021, 1, ltab011.	1.2	13
12	Perspectives in immunotherapy: meeting report from the "ImmunoTherapy Bridge" (December 4th-5th,) Tj ETQq0 0 0 3gBT /Over	1.8	0
13	Association between incidental statin use and skeletal myopathies in patients treated with immune checkpoint inhibitors. <i>Immunotherapy Advances</i> , 2021, 1, ltab014.	1.2	10
14	Understanding and treating the inflammatory adverse events of cancer immunotherapy. <i>Cell</i> , 2021, 184, 1575-1588.	13.5	111
15	Checkpoint blockade toxicities: Insights into autoimmunity and treatment. <i>Seminars in Immunology</i> , 2021, 52, 101473.	2.7	11
16	Temporal Trends and Outcomes Among Patients Admitted for Immune-Related Adverse Events: A Single-Center Retrospective Cohort Study from 2011 to 2018. <i>Oncologist</i> , 2021, 26, 514-522.	1.9	18
17	clAP1/2 antagonism eliminates MHC class II-negative tumors through T cell-dependent reprogramming of mononuclear phagocytes. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	25
18	Inhibition of CDK4/6 Promotes CD8 T-cell Memory Formation. <i>Cancer Discovery</i> , 2021, 11, 2564-2581.	7.7	58

#	ARTICLE	IF	CITATIONS
19	Impact of multidisciplinary severe immunotherapy complication service on outcomes for cancer patients receiving immune checkpoint inhibition.. Journal of Clinical Oncology, 2021, 39, 2654-2654.	0.8	0
20	Multi-detector computed tomography (MDCT)-based severity score as a prognostic tool in patients with suspected immune checkpoint inhibitor therapy associated colitis. European Radiology, 2021, 31, 8868-8878.	2.3	2
21	Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. , 2021, 9, e002890.		87
22	Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data. , 2021, 9, e002896.		20
23	Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer. , 2021, 9, e002886.		9
24	Immune Checkpoint Inhibitor Colitis: Resident Memory Unleashed. Gastroenterology, 2021, 161, 1106-1108.	0.6	3
25	Bamlanivimab Efficacy in Older and High-BMI Outpatients With COVID-19 Selected for Treatment in a Lottery-Based Allocation Process. Open Forum Infectious Diseases, 2021, 8, ofab546.	0.4	6
26	Editorial: Penetration of food protein through the oesophageal mucosa- is this where EoE starts?. Alimentary Pharmacology and Therapeutics, 2021, 53, 447-448.	1.9	1
27	Immune-related adverse events in the gastrointestinal tract: diagnostic utility of upper gastrointestinal biopsies. Histopathology, 2020, 76, 233-243.	1.6	66
28	Diagnosis and Management of Rare Immune-Related Adverse Events. Oncologist, 2020, 25, 6-14.	1.9	31
29	Prognostic implications of co-occurring dermatologic and gastrointestinal toxicity from immune checkpoint inhibition therapy for advanced malignancies: A retrospective cohort study. Journal of the American Academy of Dermatology, 2020, 82, 743-746.	0.6	9
30	Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease. Journal of Clinical Oncology, 2020, 38, 576-583.	0.8	135
31	Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. Oncologist, 2020, 25, e398-e404.	1.9	10
32	Understanding and Overcoming the Inflammatory Toxicities of Immunotherapy. Cancer Immunology Research, 2020, 8, 1230-1235.	1.6	10
33	Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. New England Journal of Medicine, 2020, 383, 2333-2344.	13.9	1,102
34	Immune receptor inhibition through enforced phosphatase recruitment. Nature, 2020, 586, 779-784.	13.7	59
35	Immune-related adverse events: what we've learned and where we're heading. Expert Review of Anticancer Therapy, 2020, 20, 727-730.	1.1	0
36	SARS-CoV-2 viral load is associated with increased disease severity and mortality. Nature Communications, 2020, 11, 5493.	5.8	702

#	ARTICLE	IF	CITATIONS
37	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors. <i>Supportive Care in Cancer</i> , 2020, 28, 6119-6128.	1.0	20
38	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune checkpoint inhibitor endocrinopathies and the role of advanced practice providers in the management of immune-mediated toxicities. <i>Supportive Care in Cancer</i> , 2020, 28, 6175-6181.	1.0	15
39	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors. <i>Supportive Care in Cancer</i> , 2020, 28, 6159-6173.	1.0	11
40	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors. <i>Supportive Care in Cancer</i> , 2020, 28, 6129-6143.	1.0	28
41	Cancer immunotherapy-related adverse events: causes and challenges. <i>Supportive Care in Cancer</i> , 2020, 28, 6111-6117.	1.0	22
42	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity. <i>Supportive Care in Cancer</i> , 2020, 28, 6145-6157.	1.0	14
43	Diagnostic utility of CT for suspected immune checkpoint inhibitor enterocolitis. , 2020, 8, e001329.		11
44	Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis. , 2020, 8, e000451.		39
45	Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor-induced colitis. <i>Cancer</i> , 2020, 126, 3758-3767.	2.0	37
46	Gastrointestinal and Hepatic Complications of Immunotherapy: Current Management and Future Perspectives. <i>Current Gastroenterology Reports</i> , 2020, 22, 15.	1.1	20
47	Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy. <i>Cell</i> , 2020, 182, 655-671.e22.	13.5	259
48	Immune checkpoint inhibitor-associated celiac disease. , 2020, 8, e000958.		38
49	Neoleukin-2 enhances anti-tumour immunity downstream of peptide vaccination targeted by an anti-MHC class II VHH. <i>Open Biology</i> , 2020, 10, 190235.	1.5	11
50	Reply to Y. Inagaki et al. <i>Journal of Clinical Oncology</i> , 2020, 38, 1749-1750.	0.8	1
51	Improved Antitumor Efficacy of Chimeric Antigen Receptor T Cells that Secrete Single-Domain Antibody Fragments. <i>Cancer Immunology Research</i> , 2020, 8, 518-529.	1.6	54
52	Time to dissect the autoimmune etiology of cancer antibody immunotherapy. <i>Journal of Clinical Investigation</i> , 2020, 130, 51-61.	3.9	66
53	Association of vitamin D intake with decreased risk of immune checkpoint inhibitor-induced colitis.. <i>Journal of Clinical Oncology</i> , 2020, 38, 89-89.	0.8	4
54	The Association Between Symptoms and COVID-19 Test Results Among Healthcare Workers. <i>Annals of Surgery</i> , 2020, 272, e329-e332.	2.1	5

#	ARTICLE	IF	CITATIONS
55	Colitis after checkpoint blockade: A retrospective cohort study of melanoma patients requiring admission for symptom control. <i>Cancer Medicine</i> , 2019, 8, 4986-4999.	1.3	27
56	Programmable bacteria as cancer therapy. <i>Nature Medicine</i> , 2019, 25, 1030-1031.	15.2	29
57	Budesonide treatment for microscopic colitis from immune checkpoint inhibitors. , 2019, 7, 292.		63
58	SMAC mimetics throw a molecular switch to control T _H 17 responses. <i>Science Signaling</i> , 2019, 12, .	1.6	1
59	Concurrent therapy with immune checkpoint inhibitors and TNF± blockade in patients with gastrointestinal immune-related adverse events. , 2019, 7, 226.		89
60	Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities. <i>Trends in Immunology</i> , 2019, 40, 511-523.	2.9	180
61	GM-CSF, IL-3, and IL-5 Family of Cytokines: Regulators of Inflammation. <i>Immunity</i> , 2019, 50, 796-811.	6.6	274
62	Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 7624-7631.	3.3	205
63	Antitumor response to microscopic melanoma in the gastric mucosa mimicking ipilimumab-induced gastritis. , 2019, 7, 41.		10
64	Cancer Immunotherapy: Beyond Checkpoint Blockade. <i>Annual Review of Cancer Biology</i> , 2019, 3, 55-75.	2.3	102
65	De novo design of potent and selective mimics of IL-2 and IL-15. <i>Nature</i> , 2019, 565, 186-191.	13.7	362
66	Factors associated with severity of immune checkpoint inhibitor gastroenterocolitis requiring hospitalization in melanoma patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, 81-81.	0.8	0
67	Flu vaccination rate of patients with severe immune-related adverse events.. <i>Journal of Clinical Oncology</i> , 2019, 37, e18234-e18234.	0.8	1
68	Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1â€™Specific VHHs. <i>Cancer Immunology Research</i> , 2018, 6, 389-401.	1.6	68
69	Antiâ€™CTLA-4 therapy requires an Fc domain for efficacy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 3912-3917.	3.3	121
70	IAP Antagonists Enhance Cytokine Production from Mouse and Human iNKT Cells. <i>Cancer Immunology Research</i> , 2018, 6, 25-35.	1.6	27
71	Regulation of innate and adaptive antitumor immunity by IAP antagonists. <i>Immunotherapy</i> , 2018, 10, 787-796.	1.0	51
72	Diagnosis and Management of Hepatitis in Patients on Checkpoint Blockade. <i>Oncologist</i> , 2018, 23, 991-997.	1.9	86

#	ARTICLE	IF	CITATIONS
73	Characterization of immune related hepatitis (irH) from immune checkpoint inhibitors (ICIs).. Journal of Clinical Oncology, 2018, 36, 3087-3087.	0.8	2
74	Severe immune-related adverse effects (irAE) requiring hospital admission in patients treated with immune checkpoint inhibitors for advanced malignancy: Temporal trends and clinical significance.. Journal of Clinical Oncology, 2018, 36, 3096-3096.	0.8	4
75	Inpatient admissions related to immune-related adverse effects (irAE) among patients treated with immune checkpoint inhibitors for advanced malignancy: A tsunami is coming, but are we ready?. Journal of Clinical Oncology, 2018, 36, 127-127.	0.8	10
76	Clinical Dosing Regimen of Selinexor Maintains Normal Immune Homeostasis and T-cell Effector Function in Mice: Implications for Combination with Immunotherapy. Molecular Cancer Therapeutics, 2017, 16, 428-439.	1.9	25
77	Targeting Immunotherapy to the Tumor Microenvironment. Journal of Cellular Biochemistry, 2017, 118, 3049-3054.	1.2	54
78	Predicting the response to CTLA-4 blockade by longitudinal noninvasive monitoring of CD8 T cells. Journal of Experimental Medicine, 2017, 214, 2243-2255.	4.2	187
79	Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract. Frontiers in Immunology, 2017, 8, 1547.	2.2	125
80	Durable antitumor responses to CD47 blockade require adaptive immune stimulation. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E2646-54.	3.3	272
81	Clinical Dosing Regimen of Selinexor Maintains Normal Immune Homeostasis and T Cell Effector Function in Mice: Implications for Combination with Immunotherapy. Blood, 2016, 128, 2525-2525.	0.6	0
82	Use of ¹⁸ F-2-Fluorodeoxyglucose to Label Antibody Fragments for Immuno-Positron Emission Tomography of Pancreatic Cancer. ACS Central Science, 2015, 1, 142-147.	5.3	85
83	Transnuclear TRP1-Specific CD8 T Cells with High or Low Affinity TCRs Show Equivalent Antitumor Activity. Cancer Immunology Research, 2013, 1, 99-111.	1.6	45
84	A dual role for the immune response in a mouse model of inflammation-associated lung cancer. Journal of Clinical Investigation, 2011, 121, 2436-2446.	3.9	82
85	IAP inhibitors enhance co-stimulation to promote tumor immunity. Journal of Experimental Medicine, 2010, 207, 2195-2206.	4.2	116
86	Immune Therapy for Cancer. Annual Review of Immunology, 2009, 27, 83-117.	9.5	545
87	Inciting inflammation: the RAGE about tumor promotion. Journal of Experimental Medicine, 2008, 205, 267-270.	4.2	45
88	Progressive chronic kidney function decline as a clinical presentation of immune checkpoint inhibitor-associated nephrotoxicity. Journal of Onco-Nephrology, 0, , 239936932210877.	0.3	1
89	Performance of a Triage Protocol for Monoclonal Antibodies in a Mixed Vaccinated and Unvaccinated Cohort of Covid-19 Patients Treated with Intravenous Infusion or Subcutaneous Injection. Open Forum Infectious Diseases, 0, , .	0.4	2